Summary

FDA's August 2026 proposal would require GRAS notices for certain uses of substances in human and animal food if the rule is finalized. The immediate task for food ingredient companies is to identify which U.S. uses currently rely on an independent GRAS conclusion and whether the evidence for those uses can support the exact commercial grade and intended conditions of use. Priority gaps may involve manufacturing changes, specifications, use levels, foreign-language records, confidentiality claims, and evidence for qualifying uses already in interstate commerce. One distinction is especially important: possessing technical data does not automatically determine who is responsible for a regulatory submission. Companies should review both evidence coverage and submission responsibility before assuming that an existing GRAS position, no-questions letter, or commercial record is sufficient. The proposal remains open for comment and has not created a current mandatory filing obligation.

The News in Brief

FDA announced the proposed change on August 10, 2026, and the proposed rule was published in the Federal Register on August 11. Comments are due by December 9, 2026.

Under the current framework, a person may conclude that a substance is generally recognized as safe (GRAS) under specified conditions of intended use without submitting a GRAS notice to FDA. The 2026 proposed GRAS rule would require notification for certain uses unless an exception applies.

The proposal includes potential exceptions for specified situations, including certain uses already covered by an FDA no-questions letter, uses listed or affirmed as GRAS under applicable regulations, and qualifying food-contact pathways.

Those exceptions depend on the substance and conditions of use actually covered. An ingredient name by itself does not establish that a current commercial grade or application remains within an earlier regulatory position.

Proposed Timeline and Current Status

These periods remain proposed. Companies should not treat them as current compliance deadlines.

Which Existing Uses Deserve the First Review?

A useful first step is to identify uses where the regulatory basis is most likely to depend on evidence that has changed, is fragmented, or has never been filed with FDA.

Independent GRAS Conclusions Without an FDA-Filed Notice

These uses sit closest to the proposed policy change.

The first question is whether the exact current substance and intended use rely on an independent GRAS conclusion without an FDA-filed notice. This should be established before companies begin collecting additional documentation.

The proposal does not mean that every food ingredient would automatically require a new GRAS submission.

Commercial Grades That Have Changed Since Earlier Evidence Was Generated

An earlier no-questions letter may not necessarily cover a current use if significant differences exist in identity, manufacturing process, food categories, use levels, technical effect, or specifications.

For suppliers and buyers, this creates a comparability test:

Does the evidence supporting the earlier GRAS position still represent the commercial grade and intended use being supplied today?

A product name or "food grade" designation cannot answer that question on its own.

Foreign-Language Supporting Records

The proposal would require accurate and complete English translations for foreign-language material submitted in or referenced by a GRAS notice.

Potential gaps may therefore exist in older:

• Manufacturing descriptions;
• Safety reports;
• Analytical studies;
• Historical-use records;
• Supporting literature.

For global suppliers, translation readiness can become a regulatory documentation issue even when the original technical evidence already exists.

Existing Uses With Weak Historical Records

The proposed streamlined pathway for certain existing uses introduces another question: can the company demonstrate that the relevant substance under the relevant conditions of use was already in interstate commerce before the effective date of a future final rule?

Long commercial history is useful only when the relevant use can be linked to dated evidence.

Proposed-Rule Triggers That Need Different Evidence

The most useful readiness review is not a generic document checklist. Different parts of the proposal raise different evidence questions.

This table is a readiness framework, not an FDA determination of eligibility. Final requirements may change before a final rule is issued.

Existing Commercial Uses Need Their Own Evidence Check

FDA proposes a time-limited streamlined submission pathway for certain substances already introduced into interstate commerce under the GRAS provision before the effective date of a future final rule.

For qualifying uses, the proposed submission would identify the submitter, substance and intended conditions of use, including relevant foods, use levels and purpose. It would also require evidence that the substance under those conditions was already in interstate commerce before the final rule's effective date.

This creates a documentation issue that differs from preparing a complete GRAS scientific dossier.

Historical sales records, customer specifications, product codes, regulatory correspondence or other dated commercial records may become relevant where they can link a specific substance to a specific use.

The proposal does not establish one universal document as sufficient evidence of historical commercial use. Companies should avoid assuming that an invoice or historic product listing alone will resolve the question.

The streamlined pathway would also have limits. Certain prior FDA regulatory histories could prevent a use from qualifying.

Filing a GRAS Notice Would Not Equal FDA Approval

Mandatory notification, if finalized, would not automatically convert GRAS into a conventional premarket approval system.

Under the proposal, FDA would distinguish between submitting information, FDA filing the submission as a GRAS notice, and the agency's later substantive evaluation.

FDA proposes an initial filing assessment within 45 days. Filing would indicate that the submission has passed that initial procedural stage.

It would not mean that FDA has determined the substance or use to be GRAS.

For procurement, quality and regulatory teams, these stages should remain separate:

submission → FDA filing → substantive GRAS evaluation

A supplier statement that a notice has been "submitted" or "filed" should therefore not be interpreted as equivalent to a favorable FDA response.

Commercial-Grade Changes Still Matter After Technical Qualification

Technical qualification and GRAS coverage answer different questions.

A sample may perform successfully in formulation work while the final manufacturing process, specification or intended use is still evolving. If the commercial grade later changes in a way that affects identity, composition, specifications or intended conditions of use, the applicability of earlier GRAS evidence may need to be reassessed.

This is the relevant qualification risk for this proposal. A technically successful sample does not establish that the final commercial grade remains represented by the same regulatory evidence.

For buyers, the practical trigger is change control: manufacturing, specification and use changes that could affect the regulatory basis should be visible during commercial qualification.

Data Ownership and Submission Responsibility Are Different Questions

The more distinctive issue raised by this proposal is not simply where evidence is stored.

A company may possess important technical information without being the party responsible for a regulatory submission.

For the proposed Subpart F streamlined pathway, FDA would define the submitter as the person responsible for the submission even if another party, such as an attorney, agent or qualified expert, prepares or transmits the information.

That creates a regulatory distinction between:

• Owning manufacturing information;
• Holding customer use data;
• Possessing supporting safety evidence;
• Preparing a submission;
• Being responsible for that submission.

These roles may sit with different organizations.

A manufacturer may control confidential process information. A food company may define the actual conditions of use. A consultant may prepare the GRAS analysis. A distributor may hold commercial records. None of those facts alone determines who is responsible for submitting the information under a particular pathway.

For B2B qualification, the more useful question becomes:

Can the responsible party obtain, reference and disclose enough evidence to support the exact substance and intended use?

This is especially important where confidential information cannot be freely transferred between supplier and customer.

The practical implication is that documentation gaps should not automatically be treated as material-quality failures. Some gaps are regulatory-access or responsibility issues that need to be resolved between the manufacturer, notifier, customer and other data holders.

Related FDA evidence questions are discussed in ChemicalCell's analysis of BHT and ADA data priorities, but the GRAS proposal adds a different layer: responsibility for a mandatory or streamlined submission may need to be defined explicitly.

What Buyers and Suppliers Should Recheck Now

The first useful action is a U.S. substance-and-use inventory.

Each relevant commercial use can be placed into one of several categories:

• Existing FDA no-questions letter that appears to cover the current substance and conditions of use;
• Listed or affirmed GRAS status that appears applicable;
• Another proposed exception that may apply;
• Independent GRAS conclusion without an FDA-filed notice;
• Existing commercial use that may need historical evidence;
• Regulatory basis or intended-use boundary still unclear.

The next review should focus only on the gaps relevant to that category.

For independent conclusions, the priority may be the GRAS basis and exact conditions of use.

For an existing no-questions letter, comparability between the earlier submission and current grade becomes more important.

For potential streamlined submissions, historical commercial-use evidence deserves earlier attention.

For foreign suppliers, translation and confidentiality handling may become separate workstreams.

FDA's GRAS program page should be monitored as the rulemaking progresses. As of August 13, 2026, mandatory GRAS notification has not taken effect.

What to Watch Next

The next fixed milestone is December 9, 2026, when the public-comment period closes.

After that point, the most important issues to monitor are whether FDA changes:

• The scope of mandatory notification;
• Exceptions for existing regulatory positions;
• The streamlined pathway for existing uses;
• Translation and confidentiality requirements;
• Filing procedures;
• Proposed effective and compliance periods.

Until a final rule is published, companies should treat the proposal as a reason to identify regulatory-evidence gaps and submission responsibilities, rather than as a current requirement to file.

For affected food additive materials, an RFQ to ChemicalCell can include the ingredient name, commercial grade, intended U.S. use, use-level basis, current GRAS or GRN information where available, required specifications or documentation, quantity and sample requirements.